FSMDX
Price
$42.33
Change
-$0.12 (-0.28%)
Updated
Jul 31 closing price
Net Assets
52.09B
FZAMX
Price
$29.83
Change
+$0.01 (+0.03%)
Updated
Jul 31 closing price
Net Assets
2.29B
Interact to see
Advertisement

FSMDX vs FZAMX

FSMDX vs FZAMX Comparison Chart in %
View a ticker or compare two or three
VS
FSMDX vs. FZAMX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSMDX is a Buy and FZAMX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSMDX has more cash in the bank: 52.1B vs. FZAMX (2.29B). FSMDX pays higher dividends than FZAMX: FSMDX (0.76) vs FZAMX (0.28). FSMDX was incepted earlier than FZAMX: FSMDX (15 years) vs FZAMX (13 years). FZAMX (0.58) is less costly to investors than FSMDX (0.03). FZAMX is a more actively managed with annual turnover of: 62.00 vs. FSMDX (15.00). FSMDX (0) and FZAMX (0) have matching initial minimum investment requirements. FZAMX annual gain was more profitable for investors over the last year : 24.25 vs. FSMDX (18.74). FSMDX return over 5 years is better than : 42.85 vs. FZAMX (17.54).
FSMDXFZAMXFSMDX / FZAMX
Total Expense Ratio0.030.584%
Annual Report Gross Expense Ratio0.030.584%
Fund Existence15 years13 years-
Gain YTD14.62220.86770%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets52.1B2.29B2,276%
Annual Yield % from dividends0.760.28269%
Returns for 1 year18.7424.2577%
Returns for 3 years50.0936.51137%
Returns for 5 years42.8517.54244%
Returns for 10 years165.6462.66264%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HPS14.220.03
+0.21%
John Hancock Preferred Income Fund III
DEM53.700.10
+0.19%
WisdomTree Emerging Markets High Div ETF
MYCI24.68-0.01
-0.06%
State Street® My2029 Corporate Bond ETF
DVXP25.85-0.12
-0.45%
WEBs Consumer Staples XLP Dfnd Vol ETF
BIB96.61-3.71
-3.70%
ProShares Ultra Nasdaq Biotechnology